Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw unusually-strong trading volume on Monday . Approximately 5,275 shares changed hands during mid-day trading, a decline of 25% from the previous session’s volume of 6,988 shares.The stock last traded at $18.90 and had previously closed at $18.50.

Analyst Upgrades and Downgrades

AAPG has been the topic of a number of research analyst reports. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research restated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price on the stock. B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target on the stock. Finally, Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Two research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat.com, Ascentage Pharma Group International currently has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Down 3.6%

The firm’s 50-day moving average is $19.21 and its 200 day moving average is $23.11. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Institutional Investors Weigh In On Ascentage Pharma Group International

Institutional investors and hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the third quarter worth about $383,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter valued at approximately $391,000. XY Capital Ltd raised its stake in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the last quarter. Finally, UBS Group AG raised its stake in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.